In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients
Related Experiment Video
Updated: Aug 16, 2026
A Novel Method to Determine the Longitudinal Antibacterial Activity of Drug-Eluting Materials
Published on: March 3, 2023
Andrea Giacometti1, Oscar Cirioni, Wojciech Kamysz
1Institute of Infectious Diseases and Public Health, c/o Ospedale Regionale, via Conca, 71, Ancona, I-60020, Italy. anconacmi@interfree.it
Abstract:
The in vitro activity of uperin 3.6, alone or combined with six antibiotics, against gram-positive cocci, including Rhodococcus equi, methicillin-resistant staphylococci, and vancomycin-resistant enterococci, was investigated. All isolates were inhibited at concentrations of 1 to 16 mg/liter. Synergy was demonstrated when uperin 3.6 was combined with clarithromycin and doxycycline.
Insights
Uperin 3.6 shows potent in vitro activity against resistant gram-positive bacteria like MRSA and VRE. It exhibits synergistic effects when combined with clarithromycin and doxycycline, offering potential for new antimicrobial therapies.
Area of Science:
- Antimicrobial drug discovery
- Infectious disease research
- Bacteriology
Background:
- Gram-positive cocci, including methicillin-resistant staphylococci (MRSA) and vancomycin-resistant enterococci (VRE), pose significant clinical challenges.
- Novel antimicrobial agents are crucial to combat rising antibiotic resistance.
- Uperin 3.6 is a peptide with potential antimicrobial properties.
Purpose of the Study:
- To evaluate the in vitro antimicrobial activity of uperin 3.6 against various gram-positive cocci.
- To assess the synergistic potential of uperin 3.6 in combination with existing antibiotics.
Main Methods:
- In vitro susceptibility testing of uperin 3.6 against Rhodococcus equi, MRSA, and VRE isolates.
- Checkerboard assays to determine synergistic activity when uperin 3.6 was combined with six different antibiotics.
Main Results:
- Uperin 3.6 demonstrated inhibitory activity against all tested gram-positive cocci at concentrations ranging from 1 to 16 mg/liter.
- Synergistic effects were observed between uperin 3.6 and clarithromycin.
- Synergistic effects were also observed between uperin 3.6 and doxycycline.
Conclusions:
- Uperin 3.6 possesses significant in vitro activity against clinically relevant gram-positive pathogens.
- Combination therapy with uperin 3.6 and clarithromycin or doxycycline may represent a promising strategy to overcome antimicrobial resistance.
